Products

Volpara Imaging Software
Lunit
Oncology AI
Volpara Health Technologies Limited offers AI-powered software for personalized breast cancer screening, risk assessment, and mammography quality improvement, aiding in earlier detection and optimized clinical workflows.
Lunit INSIGHT CXR Triage
Lunit
Radiology & Imaging AI
Lunit INSIGHT CXR Triage is an FDA-cleared AI solution that analyzes chest X-ray images to identify and prioritize emergent cases of pleural effusion and pneumothorax, optimizing workflow in critical care settings.
Lunit INSIGHT MMG
Lunit
Oncology AI
Lunit INSIGHT MMG is an AI-powered software for 2D mammograms that assists radiologists in detecting breast cancer earlier and more accurately, enhancing diagnostic confidence and streamlining workflows.

See all 4 products →

About Lunit

Lunit is a leading medical AI software company dedicated to advancing total cancer care through innovative artificial intelligence solutions. Their comprehensive platform integrates AI across the entire cancer care continuum, from early detection and diagnosis to personalized treatment decisions and drug development.

For diagnostic imaging, Lunit offers the INSIGHT suite, which includes AI solutions for chest X-rays (Lunit INSIGHT CXR), mammography (Lunit INSIGHT MMG), and 3D digital breast tomosynthesis (Lunit INSIGHT DBT). These tools are designed to assist radiologists by enhancing the accuracy and efficiency of cancer screening and detection, identifying subtle abnormalities that might be missed by the human eye. The company’s solutions are clinically validated and have received FDA clearance and CE Mark certification, demonstrating their reliability and efficacy in real-world clinical settings globally.

In the realm of precision oncology, Lunit’s SCOPE platform provides AI-powered biomarker analysis for immuno-oncology. This includes solutions like Lunit SCOPE IO for tumor microenvironment analysis, Lunit SCOPE PD-L1 for PD-L1 expression quantification, and Lunit SCOPE IHC Suite for IHC quantification. These tools aid pathologists and researchers in predicting patient responses to immunotherapy, guiding treatment strategies, and accelerating the discovery and development of new antibody-based therapies and companion diagnostics. Lunit partners with global healthcare and biopharma leaders to deploy its AI products and drive innovation in cancer care.

Focus Areas

medical imaging breast health biomarker analysis cancer screening precision oncology digital pathology AI-powered diagnostics therapeutics drug development

Business Intelligence

Technologycloud-native, multimodal AI approach, foundation models, AI-powered medical image analytics, AI biomarkers, deep learning technology, NVIDIA Tensor Core GPUs (including NVIDIA A100 GPUs), NVIDIA Jetson edge AI platform, NVIDIA TensorRT software

What Physicians Need to Know

AI-Powered Cancer Diagnosis
Lunit INSIGHT suite (MMG, DBT, CXR) offers AI-driven analysis for medical images, enhancing the early detection of breast cancer (2D mammography, digital breast tomosynthesis) and lung abnormalities (chest X-rays). It detects 11 major thoracic abnormalities and improves accuracy, particularly in dense breasts and for interval cancers.
Precision Oncology & Biomarkers
The Lunit SCOPE platform (IO, IHC Suite, GP) provides AI-driven digital pathology analysis to unlock insights from tissue. This supports biomarker discovery, personalized treatment planning, and optimizes clinical trial efficiency by analyzing tumor microenvironments and predicting tumor characteristics from H&E slides.
Comprehensive Breast Health Ecosystem
Lunit offers an integrated breast health ecosystem, combining AI for lesion detection (Lunit INSIGHT MMG/DBT) with Volpara solutions for risk assessment (Volpara Risk Pathways, Prognosia), breast density assessment (Volpara Scorecard), quality management (Volpara Analytics, Volpara Live), and patient engagement (Volpara Patient Hub).
Advanced Risk Prediction
Utilizes a hybrid AI model that combines EMR data with objective imaging data (e.g., synthetic mammography from DBT) to provide more precise and individualized 5-year breast cancer risk assessments, exemplified by Prognosia, an FDA Breakthrough Device designated model.
Validated Clinical Performance
Lunit's AI solutions are backed by over 400+ peer-reviewed publications, are FDA-cleared and CE-certified under MDR, and are deployed in over 65 countries, demonstrating world-class performance and reliability in diverse clinical environments.
Physician Tip

For physicians, Lunit's AI solutions act as a powerful 'second pair of eyes,' significantly enhancing diagnostic confidence and accuracy by detecting 5-13% more cancers in mammography and identifying subtle abnormalities in chest X-rays that might otherwise be overlooked. This leads to earlier detection, which is crucial for improved patient outcomes and can reduce unnecessary patient callbacks. The AI streamlines workflows by providing faster image interpretation, reducing cognitive load, and enabling efficient triage, which is particularly beneficial in high-volume settings or amidst radiologist shortages. In oncology, Lunit SCOPE offers quantifiable insights from tissue, aiding in biomarker discovery and personalized treatment strategies. The systems are designed for seamless integration into existing PACS/RIS and clinical workflows, minimizing disruption and maximizing utility. Furthermore, the extensive clinical validation and regulatory approvals (FDA, CE-MDR) provide a strong foundation of trust and reliability for clinical adoption.

Lunit's AI solutions are built for seamless and stable integration into existing radiology and pathology environments. They are compatible with standard DICOM formats and integrate with leading imaging manufacturers, PACS/RIS vendors, and digital health platforms. Key partnerships include collaborations with GE Healthcare (e.g., Thoracic Care Suite, Centricity PACS, Edison Open AI Orchestrator), Fujifilm, and cloud-based PACS providers like Emergent Connect, ensuring flexible deployment options and dedicated technical support.

Products by Lunit

4 products in the directory

Volpara Imaging Software
Lunit
Oncology AI
Volpara Health Technologies Limited offers AI-powered software for personalized breast cancer screening, risk assessment, and mammography quality improvement, aiding in earlier detection and optimized clinical workflows.
Lunit INSIGHT CXR Triage
Lunit
Radiology & Imaging AI
Lunit INSIGHT CXR Triage is an FDA-cleared AI solution that analyzes chest X-ray images to identify and prioritize emergent cases of pleural effusion and pneumothorax, optimizing workflow in critical care settings.
Lunit INSIGHT MMG
Lunit
Oncology AI
Lunit INSIGHT MMG is an AI-powered software for 2D mammograms that assists radiologists in detecting breast cancer earlier and more accurately, enhancing diagnostic confidence and streamlining workflows.
Lunit INSIGHT DBT
Lunit
Oncology AI
Lunit INSIGHT DBT is an AI-powered software that enhances breast cancer detection in 3D digital breast tomosynthesis (DBT) exams, aiding radiologists with precise lesion identification, classification, and navigation to improve diagnostic accuracy and efficiency.

Videos

News, demos, and interviews about Lunit.

Loading videos...

Videos load interactively. If none appear, search YouTube for Lunit →

View all on YouTube

No press coverage or publications on file yet. Know of some? Suggest an edit →

Frequently Asked Questions

Lunit offers AI solutions like Lunit INSIGHT MMG for 2D mammography, Lunit INSIGHT DBT for 3D digital breast tomosynthesis, and Lunit INSIGHT CXR for chest X-rays. These tools enhance the detection of abnormalities, such as breast cancers (even in dense breasts) and 11 major thoracic findings, by providing high accuracy and supporting faster, more consistent interpretations by radiologists.
Lunit's SCOPE platform, including Lunit SCOPE IO, SCOPE PD-L1, and SCOPE GP, provides AI-powered digital pathology solutions for analyzing tumor microenvironments, quantifying biomarkers like PD-L1, and predicting genotypes from H&E slides. These tools accelerate biomarker development, enrich immunotherapy trials, and support more precise treatment decisions and drug development strategies for biopharma companies.
Lunit's INSIGHT products (MMG, CXR, DBT) are FDA-cleared and CE-marked under Europe's Medical Device Regulation (MDR), while Lunit SCOPE PD-L1 is CE-marked. The company ensures robust data privacy and security through ISO 27001 certification and adherence to global standards like HIPAA, GDPR, and SOC 2.
Yes, Lunit's AI solutions are designed for seamless integration with existing PACS/RIS vendors and imaging manufacturers, fitting naturally into clinical workflows without disruption. The company collaborates with industry leaders to ensure smooth operability and provides dedicated technical support to facilitate implementation and ongoing use.
Lunit offers flexible pricing models, including subscription-based and pay-per-use options, to make their AI technology more accessible and affordable for healthcare providers. The cost-effectiveness can be assessed through improved diagnostic accuracy, reduced reading times, streamlined workflows, and the potential for earlier cancer detection, which can lead to better patient outcomes and potentially lower overall treatment costs.
Lunit actively partners with leading imaging manufacturers, PACS/RIS vendors, digital health platforms, and biopharma companies globally. These collaborations ensure seamless integration of Lunit's AI into diverse clinical environments and accelerate the development and deployment of AI-powered solutions across the entire cancer care continuum, from screening to drug development.
Lunit is a global leader in medical AI, with over 10,000 customer sites in more than 65 countries and strong revenue growth, aiming for company-wide break-even in 2027. The company's long-term vision, 'Vision 2030,' focuses on becoming a platform company by expanding into wider modalities and cancer types, leveraging multimodal AI, and developing foundation models, reinforced by strategic acquisitions like Volpara Health.

Investors

Who's funded Lunit.

Related Companies

RADPAIR is an advanced AI-powered radiology platform designed to streamline radiology reporting with cutting-edge generative AI. Its innovative, web-based solution aims to enhance efficiency, accuracy, and workflow automation for radiologists. As a leader in clinical AI technology, RADPAIR is transforming the future of medical imaging and diagnostic reporting. The platform offers a fully web-based experience, […]

A2z Radiology AI is a Boston-based medical imaging AI company that develops software for comprehensive CT interpretation, initially focusing on abdomen-pelvis CT scans. The company’s primary goal is to enhance diagnostic accuracy and efficiency in medical imaging for healthcare providers by leveraging artificial intelligence. Their flagship product, a2z-Unified-Triage, is FDA-cleared radiological computer-aided triage and notification […]

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]

NTL Healthcare is a South Korean AI-powered women’s health company specializing in cervical cancer screening and diagnostics. The company has a history dating back to 1996 when it first introduced an analog cervical cancer reading system, Cervicography, to Korea. Since then, NTL Healthcare has evolved its technology, developing the world’s first remote uterine cervical cancer […]

Lumonus is a healthcare technology company that specializes in AI-powered solutions for cancer care, particularly in radiation oncology. The company’s core offering is the Lumonus AI platform, a digital oncology system with AI-native clinical infrastructure designed to automate and orchestrate critical oncology workflows. This platform aims to enhance the quality and speed of care delivery […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.